Nexalis Therapeutics (ASX:NX1)
ASX announcement history & article coverage
Transparent by design.
Announcments by Nexalis Therapeutics (ASX:NX1) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Change of Director's Interest Notice - Darryl Davies
Final Director's Interest Notice - Sean Williams
Initial Director's Interest Notice - Niv Dagan
Chair Appointment/Resignation
Removal of draft wording in the directors report HY accounts
Nexalis Therapeutics reports increased loss, funding facility cancellation, and clinical trial suspension
Half Yearly Report and Accounts
Nexalis Therapeutics reports increased half-year loss and funding facility cancellation, suspends clinical trials
Jun26 Appendix 4C Cash Flow Report
Nexalis Therapeutics reports positive operating cash flow and full repayment of RDTI funding facility; Linlithgow debt facility cancelled
Jun26 Quarterly Activities Report
Nexalis completes IRX-616a Phase 1 dosing; funding facility cancelled, clinical programs under review
Change in substantial holding